Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  Canntab Therapeutics Limited    TBF1   CA1377991023

CANNTAB THERAPEUTICS LIMITED

(TBF1)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
Business Summary
Logo Canntab Therapeutics Limited
Canntab Therapeutics Ltd, formerly Telferscot Resources Inc, is a Canada-based company engaged in alternatywe medicine sector. The Company is dedicated to the research and development of oral dosage therapeutic formulations of cannabis and a range of oral dosage products that treat different ailments by delivering a uniform dosage of medicinal cannabis extract. The Company developed bi-layered tablets that offer an immediate dosage and therefore immediate release of active ingredients, combined with its patent pending extended release formulations. Its Gel Capsules offer doctors and patients a uniform amount of THC/CBD oil extract, in a quick dissolving gel capsule. The Companys flash melt tablets are designed to dissolve immediately when placed under the tongue. They deliver an dosage to the patient, offering instant relief.
Sales per Business
20192020Delta
CAD (in Million)%CAD (in Million)%
Cannabinoids and Terpenes0.240100%0.133100% -44.44%
Sales per region
20192020Delta
CAD (in Million)%CAD (in Million)%
Canada0.240100%0.133100% -44.44%
Managers and Directors
NameAgeSinceTitle
Lawrence Latowsky602020Executive Chairman & Chief Executive Officer
Jeffrey W. Renwick522020President, Director & Head-Manufacturing
Richard Goldstein592018Chief Financial Officer & Director
Joshi Laxminarayan-2020Chief Scientific Officer
Vitor Manuel Fonseca672018Independent Director
Barry M. Polisuk57-Secretary & Director
Eric Malinski-2018Marketing Director
Frank Candido552018Head-Business Development & Investor Relations
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 35,451,437 27,151,437 76.6% 0 0.0% 76.6%
Shareholders
NameEquities%
Richard Goldstein 3,858,000 11.7%
Jeffrey W. Renwick 3,838,000 11.6%
Barry M. Polisuk 340,000 1.03%
Lawrence Latowsky 244,000 0.74%
Vitor Manuel Fonseca 20,000 0.060%